Business Opportunities
NSCLC prognosis method for outlicense
New patented and completely developed prognosis method for NCSLC response for different treatments is available
Jerusalem Calatrava bridge
for outlicense.
New drugs for the treatment of neurodegeneration as consequence of CNS insults
Brain ischemia (stroke), anoxia, hemorrhage, traumatic brain injury, exposure to nerve gases
– The product has been qualified by FDA for a fast track drug development program.
– The Company has signed an agreement with the US Army to begin trials against poisonous war gases
Switch-peptides that act as regulators of immune processes
Applications:
– Amyotrophic Lateral Sclerosys Therapy
– Lupus Therapy
– Regulation of Autoimmune Diseases
– Prevention of Graft vs Host Disease and Transplantation Rejection
Proof of concept in animals in most of the applications
The Company is looking for investments or codevelopment
Radio Frequency dynamic 3-dimensional system to visualize on real time with high resolution and high refreshment rate internal organs of the body.
– The Company has been fully funded until now by the inventors.
– The Company will begin by developing a heart non-invasive diagnose system, that will be followed by other organs
– The Company has an experienced management team, able to work under extreme pressure and design state of the art systems on the 3-D vision RF field.
Barcelona Calatrava Tower
Looking for investments or codevelopment opportunities
Small molecules to treat solid cancers
Proof of concept for solid tumors on sp-1 binding inhibitor target
The Company is looking for investors
Artificial Liver system (USA-Hong Kong-Continental China)
· The Company has developed an artificial liver to be used on patients that are waiting for transplantation.
· Numerous attempts have been made over the past 30 years to develop a surrogate technique to provide either partial or total metabolic support for the patient with a failing liver.
· The clinical objective is to provide a temporary liver assist until a patient’s own liver regenerates or until a liver transplant can be performed.
Description of the Technology:
The Bioartificial Liver System comprises an extracorporeal process for continuously withdrawing a patient’s whole venous blood, maintaining temperature, oxygenating to arterial levels, adjusting pH to 7.2, and perfusing a hollow fiber bioreactor charged with primary porcine hepatocytes before returning the blood to the patient.
Early Clinical Results:
Five patients have received treatments under this proto
col, four of which have sufficient data for evaluation. No serious or unexpected adverse events were observed. Patients showed an improvement in encephalopathy, improved blood ammonia and lactate levels and improved pulmonary function during their participation in the study. An additional 10 patients will be enrolled to complete the Phase I/II study. 150 patients will be necessary for Phase III.
- US Market Approval: in 48 months approx.
- China Market Approval: expected in 24 months
- Hong- Kong Market Approval: expected in 14 months
Hong Kong is expected to accept product registration based on a single site, open label Phase I/II study and require 14 months.
The Company is looking for investments
Fundraising for Company that manages three incubators
The incubators operate in Biotech, Medtech and Cleantech
The Management Company was incorporated in 1993 and has done several exits with success
Please contact us to obtain more information
Fundraising for Venture Capital that invests in Biotech Companies
Please contact us to obtain more information
